206 related articles for article (PubMed ID: 28904125)
21. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
22. Mapping a conserved conformational epitope from the M protein of group A streptococci.
Relf WA; Cooper J; Brandt ER; Hayman WA; Anders RF; Pruksakorn S; Currie B; Saul A; Good MF
Pept Res; 1996; 9(1):12-20. PubMed ID: 8727479
[TBL] [Abstract][Full Text] [Related]
23. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
24. The quest for GAS vaccine.
Pandey M; Good MF
Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
[No Abstract] [Full Text] [Related]
25. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
27. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
Dale JB
Vaccine; 1999 Jan; 17(2):193-200. PubMed ID: 9987154
[TBL] [Abstract][Full Text] [Related]
28. Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.
Aranha MP; Penfound TA; Spencer JA; Agarwal R; Baudry J; Dale JB; Smith JC
J Biol Chem; 2020 Mar; 295(12):3826-3836. PubMed ID: 32029479
[TBL] [Abstract][Full Text] [Related]
29. In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.
Nordström T; Malcolm J; Magor G; Good MF; Batzloff MR
Clin Vaccine Immunol; 2012 Dec; 19(12):1984-7. PubMed ID: 23081813
[TBL] [Abstract][Full Text] [Related]
30. Immune response to superoxide dismutase in group A streptococcal infection.
McMillan DJ; Davies MR; Good MF; Sriprakash KS
FEMS Immunol Med Microbiol; 2004 Apr; 40(3):249-56. PubMed ID: 15039102
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
32. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
[TBL] [Abstract][Full Text] [Related]
33. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.
Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Infect Immun; 2003 May; 71(5):2373-83. PubMed ID: 12704107
[TBL] [Abstract][Full Text] [Related]
34. Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.
Klonoski JM; Hurtig HR; Juber BA; Schuneman MJ; Bickett TE; Svendsen JM; Burum B; Penfound TA; Sereda G; Dale JB; Chaussee MS; Huber VC
Vaccine; 2014 Sep; 32(40):5241-9. PubMed ID: 25077423
[TBL] [Abstract][Full Text] [Related]
35. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci.
Brandt ER; Hayman WA; Currie B; Carapetis J; Wood Y; Jackson DC; Cooper J; Melrose WD; Saul AJ; Good MF
Immunology; 1996 Nov; 89(3):331-7. PubMed ID: 8958044
[TBL] [Abstract][Full Text] [Related]
36. Group A streptococcus epidemiology and vaccine implications.
Cohen-Poradosu R; Kasper DL
Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
[No Abstract] [Full Text] [Related]
37. Development of conformational mimetics of conserved Streptococcus pyogenes minimal epitope as vaccine candidates.
Zhong W; Skwarczynski M; Toth I
Curr Drug Deliv; 2009 Oct; 6(5):520-7. PubMed ID: 19863488
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine.
Bruner M; James A; Beall B; Carlone GM; Ades E; Johnson S; Guarner J; Sampson J
Vaccine; 2003 Jun; 21(21-22):2698-703. PubMed ID: 12798606
[TBL] [Abstract][Full Text] [Related]
39. M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus.
Skwarczynski M; Kamaruzaman KA; Srinivasan S; Zaman M; Lin IC; Batzloff MR; Good MF; Toth I
Curr Drug Deliv; 2013 Feb; 10(1):39-45. PubMed ID: 22998043
[TBL] [Abstract][Full Text] [Related]
40. Immunity to group a streptococcal M proteins: forging a single-edged sword.
Madoff LC
Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
